Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SC teprotumumab vs placebo in active thyroid eye disease
jRCT2031240294Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED) comparing Teprotumumab SC with Placebo SC (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Sep 2024; status: active, not recruiting.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on jRCT2031240294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240294.